Anaplastic Large Cell Lymphoma (ALCL) - Pipeline Review, H2 2016 - Global Markets Direct - Market Research

Anaplastic Large Cell Lymphoma (ALCL) - Pipeline Review, H2 2016

Anaplastic Large Cell Lymphoma (ALCL) - Pipeline Review, H2 2016 - Global Markets Direct - Market Research
Anaplastic Large Cell Lymphoma (ALCL) - Pipeline Review, H2 2016
Published Jul 20, 2016
104 pages — Published Jul 20, 2016
Price US$ 2,000.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Directs, Anaplastic Large Cell Lymphoma (ALCL) - Pipeline Review, H2 2016, provides an overview of the Anaplastic Large Cell Lymphoma (ALCL) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Anaplastic Large Cell Lymphoma (ALCL), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Anaplastic Large Cell Lymphoma (ALCL) and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Anaplastic Large Cell Lymphoma (ALCL)
- The report reviews pipeline therapeutics for Anaplastic Large Cell Lymphoma (ALCL) by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Anaplastic Large Cell Lymphoma (ALCL) therapeutics and enlists all their major and minor projects
- The report assesses Anaplastic Large Cell Lymphoma (ALCL) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Anaplastic Large Cell Lymphoma (ALCL)

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Anaplastic Large Cell Lymphoma (ALCL)
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identi

  
Source:
Document ID
GMDHC8288IDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents24
  List of Tables51
  List of Figures51
Introduction61
  Global Markets Direct Report Coverage61
Anaplastic Large Cell Lymphoma (ALCL) Overview71
Therapeutics Development81
  Pipeline Products for Anaplastic Large Cell Lymphoma (ALCL) Overview81
Anaplastic Large Cell Lymphoma (ALCL) Therapeutics under Development by Companies91
Anaplastic Large Cell Lymphoma (ALCL) Pipeline Products Glance103
  Late Stage Products101
  Clinical Stage Products111
  Early Stage Products121
Anaplastic Large Cell Lymphoma (ALCL) Products under Development by Companies131
Anaplastic Large Cell Lymphoma (ALCL) Companies Involved in Therapeutics Development148
  Ariad Pharmaceuticals, Inc.141
  AstraZeneca Plc151
  Bayer AG161
  Celon Pharma Sp. z o.o.171
  Pfizer Inc.181
  Sareum Holdings Plc191
  Seattle Genetics, Inc.201
  Teva Pharmaceutical Industries Ltd.211
Anaplastic Large Cell Lymphoma (ALCL) Therapeutics Assessment229
  Assessment by Monotherapy Products221
  Assessment by Target232
  Assessment by Mechanism of Action252
  Assessment by Route of Administration272
  Assessment by Molecule Type292
Drug Profiles3150
  AdIL-24 Drug Profile312
  AZD-3463 Drug Profile331
  brentuximab vedotin Drug Profile3421
  brigatinib Drug Profile559
  CEP-37440 Drug Profile641
  copanlisib hydrochloride Drug Profile654
  crizotinib Drug Profile697
  Drug to Inhibit ALK for Anaplastic Large Cell Lymphoma Drug Profile761
  SAR-3 Drug Profile771
  SAR-4 Drug Profile782
  SH-7129 Drug Profile801
Anaplastic Large Cell Lymphoma (ALCL) Dormant Projects811
Anaplastic Large Cell Lymphoma (ALCL) Discontinued Products821
Anaplastic Large Cell Lymphoma (ALCL) Product Development Milestones8320
  Featured News &Press Releases831
    Jan 22, 2016: European Commission Approves Label Variation for ADCETRIS to Include Data on Retreatment of Adult Patients with Relapsed or Refractory Hodgkin Lymphoma and Systemic Anaplastic Large Cell Lymphoma831
    Jun 17, 2015: Seattle Genetics Announces Multiple ADCETRIS (Brentuximab Vedotin) Data Presentations at the International Conference on Malignant Lymphoma841
    Dec 07, 2014: Seattle Genetics and Takeda Announce Four-Year Survival Data from ADCETRIS (Brentuximab Vedotin) Pivotal Trial in Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma at ASH Annual Meeting852
    Dec 06, 2014: Seattle Genetics and Takeda Report Phase 3 AETHERA Clinical Trial Data from ADCETRIS (Brentuximab Vedotin) in Post-Transplant Hodgkin Lymphoma Patients at Risk of Relapse at ASH Annual Meeting872
    Nov 07, 2014: Seattle Genetics to Present Clinical Data from Broad ADCETRIS (Brentuximab Vedotin) Development Program and Novel Antibody-Drug Conjugates at ASH 2014892
    Nov 06, 2014: Takeda Announces Abstracts for ADCETRIS (brentuximab vedotin) in Hodgkin Lymphoma, Systemic Anaplastic Large Cell Lymphoma to be Presented at 56th American Society of Hematology Annual Meeting911
    Sep 24, 2014: Seattle Genetics Highlights Updated Progression-Free Survival and Overall Survival Data from ADCETRIS (Brentuximab Vedotin) Frontline PTCL Phase 1 Clinical Trial at the ESMO 2014 Congress921
    Apr 17, 2014: ADCETRIS 50mg for intravenous drip infusion", Treatment for Patients with CD30 Positive Relapsed or Refractory Hodgkin Lymphoma or Relapsed or Refractory Anaplastic Large Cell Lymphoma Now Available in Japan931
    Jan 17, 2014: Seattle Genetics Announces ADCETRIS Approval in Japan for the Treatment of Relapsed or Refractory Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma931
    Jun 21, 2013: Seattle Genetics Highlights Adcetris Clinical Data At International Conference On Malignant Lymphoma942
    Jun 19, 2013: Takeda And Seattle Genetics Highlight Post-Hoc Analysis Examining Progression-free Survival With Adcetris At International Conference On Malignant Lymphoma962
    Jun 01, 2013: Takeda Highlights Data From Phase I/II Clinical Trial Examining Use Of Adcetris in Pediatric Patients With Hodgkin Lymphoma Or Systemic Anaplastic Large Cell Lymphoma981
    May 14, 2013: Seattle Genetics Announces Adcetris Supplemental BLA Accepted For Filing By FDA991
    Mar 22, 2013: Takeda Submits New Drug Application For Brentuximab Vedotin In Japan1001
    Mar 18, 2013: Seattle Genetics Submits Supplemental BLA To FDA For Retreatment And Extended Duration Of Therapy With Adcetris In Relapsed Hodgkin Lymphoma And Systemic ALCL1012
Appendix1032
  Methodology1031
  Coverage1031
  Secondary Research1031
  Primary Research1031
  Expert Panel Validation1031
  Contact Us1031
  Disclaimer1041

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Anaplastic Large Cell Lymphoma (ALCL) - Pipeline Review, H2 2016" Jul 20, 2016. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Anaplastic-Large-Cell-Lymphoma-ALCL-Pipeline-Review-H2-2016-2088-16251>
  
APA:
Global Markets Direct - Market Research. (2016). Anaplastic Large Cell Lymphoma (ALCL) - Pipeline Review, H2 2016 Jul 20, 2016. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Anaplastic-Large-Cell-Lymphoma-ALCL-Pipeline-Review-H2-2016-2088-16251>
  
US$ 2,000.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.